Document:

EX-10.16

 Exhibit 10.16 
 AMENDED AND RESTATED 
 SERVICES, RESELLER AND NON-COMPETITION AGREEMENT

 THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is
made and entered into effective as of June 27, 2013 (the “Effective Date”) by and between The Advisory Board Company, a Delaware corporation (“ABCO”), and Evolent Health, Inc. (f/k/a VPHealth, Inc.), a Delaware
corporation (“Evolent”), (each, a “Party”, and collectively, the “Parties”). 
 RECITALS 
 WHEREAS, ABCO and Evolent entered into a Services,
Reseller and Non-Competition Agreement (the “Original Agreement”), effective as of August 31, 2011 (the “Original Effective Date”); 

WHEREAS, since entering into the Original Agreement, Evolent and ABCO have continued to explore ways to improve the efficiency and
implementation of their relationship; and 
 WHEREAS, as a result of the foregoing efforts, the Parties have
agreed to amend and restate the Original Agreement as set forth in this Agreement. 
 NOW, THEREFORE, in
consideration of the above recitals, the terms and conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 

1. DEFINITIONS. For purposes of this Agreement: 
 1.1 “ABCO Restricted Products and Services” means (a) care management services including, but not limited to, traditional disease management services, direct patient outreach
and other service-based care management offerings (e.g., readmissions management teams, nurse call centers, on-site care management teams); (b) care management workflow software designed for and used by provider-owned payor organizations or
other entities intending to conduct active care management campaigns targeted at managing population health/longitudinal outcomes (i.e, solutions that are the same as or substantially similar to (i.e. functionality that is redundant in substantial
and material respects with) HealthPlaNet); (c) services primarily intended to support cost reduction and benefit changes for health system employees; (d) consulting services comparable and competitive with blueprint consulting services
offered by Evolent as of the Effective Date (“Blueprint Services”), (e) Exclusive TPA Services or (f) Crimson Care Registry products. For the avoidance of doubt, Restricted Products and Services does not include behavioral
health-related services or software (e.g., Askesis Development Group software), services similar to those offered by UPMC WorkPartners (e.g., “Take-a-Healthy-Step” or similar health and wellness programs, occupational medicine, on-site
clinic implementation and administration, employee assistance services, absence management or workers’ compensation services), or software or solutions similar to those offered by EBenefits Solutions, LLC. 

1.2 “Active Sales Process”, with respect to any Person as of any date on which Evolent proposes to add such
Person to the list of Evolent Top Prospects, means such Person (a) is not an Evolent Client as of such date and (b) either (i) has purchased ABCO Restricted Products and Services from ABCO prior to such date or (b) was engaged in
active discussions with ABCO about acquiring ABCO Restricted Products and Services (including, but not 

  
 1 

 
limited to, a review of the applicable offering of ABCO Restricted Products and Services) as of such date. 
 1.3 “Affiliate” means any Person which Controls, is Controlled by, or is in common Control with, another Person. 

1.4 “Business Plan” has the meaning set forth in that certain Intellectual Property License and Data Access
Agreement between the Parties. 
 1.5 “Change of Control” with respect to any entity means a
transaction or series of related transactions in which a Person, or a group of related Persons, acquires from stockholders of the subject entity, the entity’s shares representing more than fifty percent (50%) of the outstanding voting
power of such entity. 
 1.6 “Confidential Information” means any and all technical and
non-technical information, whether conveyed verbally, in writing, electronically or by any other means, including, but not limited to, trade secrets, source code, technology, know-how and proprietary information, techniques, plans or any other
information relating to any research project, analysis, work in process, future development, scientific, engineering, marketing or business plans or financial, contractual or personnel matters relating to either Party or its present or future
products, services, sales, suppliers, identity of and information relating to customers and prospective customers, customer or prospect list, prospective employees, investors or affiliates or other proprietary information disclosed or otherwise
supplied in confidence by either Party to the other, to the extent that such information is provided pursuant to this Agreement by one Party to the other Party and is marked “confidential” or “proprietary” or that should be
reasonably understood by the Receiving Party (based on the nature of the information or the context in which the information is disclosed) should be considered confidential. Confidential Information will not include information to the extent that:
(a) such information is or becomes publicly available other than through any act or omission of either Party in breach of this Agreement; (b) such information was received by the Receiving Party, other than under an obligation of
confidentiality, from a third party who had no obligation of confidentiality to the other Party; (c) such information was in the possession of the Receiving Party at the time of the disclosure or was independently developed by the Receiving
Party, as reflected by the Receiving Party’s internal, written and dated documentation; or (d) an applicable regulation, court order or other legal process requires the disclosure of such information, provided that prior to such disclosure
the Disclosing Party will give notice to the other Party so that the other Party may take reasonable steps to oppose or limit such disclosure, so that the Disclosing Party does not disclose any more information than necessary to comply with such
legal process. The burden of proof that Confidential Information falls into any one of the above exemptions will be borne by the Party claiming such exemption with documentation or other credible evidence. 

1.7 “Control” as used with respect to any Person, means the possession, directly or indirectly, of the power to
direct or cause the direction of the management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise. 
 1.8 “Evolent Clients” means entities under a current contract with Evolent for an implementation and/or long-term services contract. 

1.9 “Evolent Top Prospects” means, as of any date, up to twenty (20) potential Evolent customers in the
Evolent sales pipeline identified by Evolent that are not Evolent 

  
 2 

 
Clients as of such date, and (a) are engaged in active discussions with Evolent regarding purchasing Evolent products and services and/or (b) are under a current contract with
Evolent for Blueprint Services or other services that do not constitute implementation or long-term services; provided, however, that (i) the list of such potential Evolent customers may be updated by Evolent on a quarterly basis, and ABCO
shall have the opportunity upon receipt of each such quarterly update to notify Evolent if any of the Persons added to such list are in an Active Sales Process with ABCO and shall therefore be removed from such list, and (ii) no Person shall
remain on the list of Evolent Top Prospects for more than (x) twelve (12) consecutive months, in the case of potential Evolent customers without a signed agreement with Evolent, or (y) twenty-four (24) consecutive months, in the
case of potential Evolent Clients that signed an agreement for Blueprint Services with Evolent before or within twelve (12) months of being added to the list of Evolent Top Prospects. 

1.10 “Exclusive TPA Services” means certain services as set forth on Schedule 1 of the UPMC Reseller Agreement
(as in effect on the Effective Date), to the extent that UPMC Health Plan, Inc., a Pennsylvania nonprofit corporation (“UPMC”), has the exclusive right to provide such services to Evolent, for resale by Evolent to its customers.

 1.11 “Disclosing Party” means a Party that provides Confidential Information to the other Party,
or the other Party’s Affiliates. 
 1.12 “Governmental Authority” means any federal, state,
municipal, local, territorial, or other governmental department, regulatory authority, judicial or administrative body, whether domestic, foreign or international. 
 1.13 “Law” means all international, federal, country, state, provincial, local and other laws, rules and regulations, declaration, decree, directive, legislative enactment, order, code,
ordinance, regulation, rule or other binding restriction of or by any Governmental Authority, as the same are promulgated, supplemented or amended from time to time. 
 1.14 “Loss” individually, and collectively, “Losses” means all claims, liabilities, obligations, losses, costs, expenses (including, without limitation, legal,
accounting and similar expenses), litigation, proceedings, fines, taxes, levies, imposts, duties, deficiencies, assessments, charges, penalties, allegations, demands, damages (including, but not limited to, actual, punitive or consequential,
foreseen or unforeseen, known or unknown, fixed or contingent, and matured or unmatured), civil and criminal violations of Law, settlements and judgments of any kind or nature whatsoever. 

1.15 “Person” means any individual, corporation, partnership, firm, joint venture, association, limited liability
company, limited liability partnership, joint-stock company, trust, joint venture, unincorporated organization, governmental, judicial or regulatory body, business unit, division or any other business entity, organization or Governmental
Authority. 
 1.16 “Receiving Party” means a Party that receives Confidential Information from
the other Party or the other Party’s Affiliates. 
 1.17 “Statement of Work” or
“SOW” means an agreement by and between ABCO and Evolent that contains the detailed description of services, scope, specifications, pricing, implementation plan, timetables, milestones, and other terms and conditions for each
procurement of services, as applicable. 

  
 3 

 1.18 “UPMC Reseller Agreement” means that certain Second Amended and
Restated Reseller, Services and Non-Competition Agreement between UPMC and Evolent dated as of [the Effective Date]. 
 2. SERVICES TO
BE PROVIDED BY ABCO. 
 2.1 General Services: 

2.1.1 Minimum Purchase. The Parties hereby acknowledge and agree that Evolent has purchased from ABCO a minimum of Two Hundred
Thousand Dollars ($200,000) of services (as described in Section 2.2.1) (the “Original Minimum Purchase”) for delivery between the Original Effective Date and the first anniversary thereof. 

2.1.2 Statements of Work. The specific description, price, service levels (if applicable) and other project, service,
and/or customer-specific terms for a particular service that may be provided by ABCO to Evolent (each, a “Service”, and collectively, the “Services”) shall be set forth in a Statement of Work that will be created on
a project by project basis. 
 2.2 Right of First Offer and Process for Invoking: 

2.2.1 Applicable Services. Throughout the Term, ABCO shall have the right of first offer to provide the following services
to Evolent and Evolent’s customers: 
 (a) Physician practice management consulting and other
physician practice management services; 
 (b) Physician incentive design services; 

(c) Medical home development consulting services; and 

(d) Performance analytics shared with physicians with the intent to improve outcomes. 

2.2.2 Process for Exercising Right of First Offer. Evolent shall notify ABCO in writing in the event Evolent desires to
receive any of the above services (“First Offer Services”). ABCO shall have a period of thirty (30) days (“First Offer Services Evaluation Period”) within which to conduct its evaluation and diligence with
respect to providing such First Offer Services. Evolent shall cooperate with ABCO and provide reasonable assistance and information to ABCO to enable ABCO to conduct its evaluation. Within five (5) business days after the expiration of such
First Offer Services Evaluation Period, ABCO shall notify Evolent in writing whether or not it wishes to provide such services to Evolent. If ABCO elects to provide such First Offer Services, Evolent agrees to engage in good faith negotiations with
ABCO, on an exclusive basis for a period of sixty (60) days, regarding the specific terms covering such First Offer Services. 
 2.3 Failure to Execute a Service Agreement for the VBC Innovation Center: The Parties acknowledge and agree that it was their intent as of the Original Effective Date to enter into a service
agreement under which Evolent would engage ABCO to provide certain consulting, development and support services in connection with the creation, launch, implementation and ongoing support of a Value-Based Care Innovation Center (the “VBC
Innovation Center”), in consideration for which Evolent would pay ABCO a fixed fee of Eight Hundred Thousand Dollars ($800,000) per year (“Fixed Fee”) for each of the first two (2) years of the term of such VBC
Innovation Center service agreement. The Parties acknowledge and 

  
 4 

 
agree that, notwithstanding the fact that they negotiated with diligence and in good faith the specific terms and conditions of such service agreement, the Parties were unable to reach an
agreement with respect to the VBC Innovation Center. Accordingly, the Original Minimum Purchase is increased to One Million Two Hundred Thousand Dollars ($1,200,000) (the “Minimum Purchase”) as follows: (a) between the Original
Effective Date and the second anniversary thereof, Evolent shall have purchased from ABCO a minimum of Seven Hundred Thousand Dollars ($700,000) of services for delivery on or prior to such second anniversary of the Original Effective Date), and
(b) inclusive of the purchases described in clause (a), between the Original Effective Date and the third anniversary thereof, Evolent shall have purchased from ABCO a minimum of One Million Two Hundred Thousand Dollars ($1,200,000) of services
for delivery on or prior to such third anniversary of the Original Effective Date); provided that, for purposes of this sentence, “services” shall include consulting, software, professional or analytic services provided from time to time
by ABCO to Evolent (other than services in connection with the provision of any office space by or on behalf of ABCO to Evolent) or, pursuant to a joint written proposal by ABCO and Evolent, to any Evolent Client. 

2.4 Reservation of Rights: For the avoidance of doubt, Evolent is not precluded from offering and providing services directly to
its customers, subject (a) to (i.e., after ABCO has had the full opportunity to exercise) ABCO’s right of first offer to provide any First Offer Services in accordance with Section 2.2) and (b) to Evolent’s compliance with
its non-competition obligations as set forth in Section 6.2. 
 2.5 Designation of Relationship Managers: In order
to support the launch and ongoing success of the exclusive reseller relationship between ABCO and Evolent, each Party agrees to designate a senior level individual who will serve as the primary liaison and “go to” contact and relationship
manager for such Party (each, a “Relationship Manager”). Each Party’s Relationship Manager’s role and responsibilities would include: (a) facilitating day-to-day communications between the Parties regarding
customer-facing activities, such as marketing, promotional and sales activities and preparing and submitting bids, proposals, responses to requests for proposals, fee estimates, Statements of Work and project plans; (b) receiving and submitting
requests between the Parties for information and/or assistance; (c) overseeing the efficient knowledge transfer and flow of information between the Parties; (d) facilitating communications between the appropriate individuals within Evolent
and ABCO, with respect to product and service offering development; and (e) providing the first level of performance review or escalation in the event of a Dispute as provided in Section 13. The Relationship Managers will meet regularly,
but no less frequently than monthly, as reasonably necessary, to maintain a good working relationship between the Parties. Each Party may change its Relationship Manager by giving the other Party reasonable notice as long as the change is
implemented in a manner that does not cause any significant disruption to each Party’s business operations and business relationship. 

3. FEES; PAYMENT TERMS; SHORTFALL. 
 3.1 Fees; Timing of Payments: Evolent shall pay ABCO the applicable fees for the Services performed by ABCO pursuant to a Statement of Work, as follows: (a) unless the Parties otherwise agree
in writing, a deposit of 50% of the total fees for the particular project shall be paid upon signing of the Statement of Work; (b) ABCO will submit an invoice to Evolent for the balance upon completion of the work; and (c) Evolent shall
pay ABCO for such invoiced amount within thirty (30) days after receipt of such invoice. 

  
 5 

 3.2 Minimum Purchase and Shortfall: Evolent agrees to pay ABCO the Minimum Purchase.
If the aggregate amount of Services actually procured by Evolent from ABCO is not equal to or greater than (a) Seven Hundred Thousand Dollars ($700,000) of services for delivery on or prior to the second anniversary of the Original Effective
Date or (b) inclusive of the purchase described in clause (a), the Minimum Purchase of services for delivery on or prior to the third anniversary of the Original Effective Date, Evolent shall pay ABCO the amount of the shortfall (i.e., the
difference between Seven Hundred Thousand Dollars ($700,000) or the Minimum Purchase amount, as applicable, less the sum of: (a) the aggregate fees for the actual amount of Services procured; and (b) any Credits (as provided in the next
sentence) (the “Shortfall”), if any, on or before August 31, 2013 or August 31, 2014, as applicable. In the event that ABCO refuses or fails, without reasonable cause, to provide any of the Services requested by Evolent
(provided the scope of the Services requested is within the scope customarily provided by ABCO), the fees that would otherwise have been applicable had ABCO agreed to provide such Services would count as a “Credit”. As of the
date hereof, no such Credits have accrued. 
 4. TERM AND RENEWAL. The initial term of this Agreement shall commence on the
Effective Date and unless sooner terminated in accordance with the terms hereof, shall continue until August 31, 2016 (“Initial Term”). Thereafter, this Agreement shall automatically be renewed for another five-year term
(“Renewal Term”) unless either Party elects to terminate this Agreement by providing the other Party with written notice of termination one hundred eighty (180) days prior to the expiration of the current term.
(“Initial Term” and “Renewal Term” collectively, the “Term”). 
 5. REFERRAL
FEES, SOLICITATION AND COMPETITION AND POST-CLOSING SERVICES. 
 5.1 Referral Fees: 

5.1.1 During the Term, ABCO will pay Evolent a sales referral fee for any sale made by ABCO that resulted from a “net” new sale
from a new customer that was not already in ABCO’s sales pipeline (i.e., a “warm lead”) or a then-current customer of ABCO generated directly by Evolent’s efforts and without any assistance from any ABCO employee or
representative (including any Evolent employee that serves on the Board of Directors of ABCO), equal to 5% of the total ABCO revenue from the new customer during the initial twelve (12) months of services under the services agreement with such
new customer. 
 5.1.2 During the Term, Evolent will pay ABCO a sales referral fee for any sale made by Evolent that resulted
from a “net” new sale from a new customer that was not already in Evolent’s sales pipeline (i.e., a “warm lead”) or a then-current customer of Evolent generated directly by ABCO’s efforts and without any assistance from
any Evolent employee or representative (including any ABCO employee that serves on the Board of Directors of Evolent), in accordance with the following terms: 
 (a) ABCO will receive a one-time referral fee for any “employee health” diagnostic, consulting or broker services provided by Evolent to a Covered Health System, equal to the lesser of $20,000
or 5% of the total Evolent revenue from the Covered Health System during the initial twelve (12) months of services under the service agreement with such Covered Health System. 

  
 6 

 (b) ABCO will receive $50,000 per year for three (3) years for
each health system joining Evolent as an Employee Health Platform Customer. An “Employee Health Platform Customer” is defined as a health system purchasing diagnostic/consulting services and ongoing medical management/health plan
services (i.e., care management, HealthPlaNet care management application, and the TPA platform, etc.). 

(c) ABCO will receive $100,000 per year for three (3) years for a health system joining Evolent as a Platform
Health Plan Customer. A “Platform Health Plan Customer” is defined as a health system purchasing ongoing medical management services, ongoing health plan outsourcing services (i.e., TPA) and health plan management services for
purposes of a licensed insurance entity with at least fifty thousand (50,000) lives (beyond the employee population). 
 (d) With the exception of making the introduction (either through an email or an in-person meeting) (to generate the “warm lead”), ABCO would not be expected to perform any actual duties or
incur actual cost to receive a referral fee. 
 (e) The annual referral fees for each referral would be capped
at the lesser of (x) 5% of annual revenue generated by Evolent for the respective customer and (y) the $50,000 or $100,000 figures described above, as applicable. 
 6. SOLICITATION AND COMPETITION. 
 6.1 Scope:

 6.1.1 Throughout the Term, ABCO agrees not to offer any ABCO Restricted Products and Services to (a) any Evolent Clients
or (b) any Evolent Top Prospects; provided, however, that ABCO shall not be restricted from making any such offer to any Evolent Top Prospect or Evolent Client with whom ABCO was, at the time such Person was identified as an Evolent Top
Prospect or became an Evolent Client, engaged in an Active Sales Process. The foregoing restrictions shall not apply in the event of a Change of Control of Evolent or in the event that ABCO ceases to be a shareholder of Evolent. 

6.1.2 None of the foregoing would prohibit ABCO from: 

(a) Marketing, offering, licensing or selling versions of any of its Crimson Population Risk Management products, or the
successors to any such products, provided that such products, or the successors to any such products, are not the same as or substantially similar to (i.e., includes functionality that is redundant in substantial and material respects with)
HealthPlaNet as it exists as of the Effective Date. 
 (b) Supporting employers with care management related
best practices and research. 
 (c) Offering traditional “dedicated advisor” support in conjunction
with ABCO’s traditional business intelligence offerings. 
 (d) Marketing, offering, licensing or selling
its employer health product. 
 (e) Providing physician management consulting and other physician management
services. 

  
 7 

 6.2 Restrictions Relating to Certain ABCO Products and Services:
Evolent shall not, until the earlier of (x) ABCO’s ceasing to be a shareholder of Evolent or (y) the seventh (7th) anniversary of the date of this Agreement, promote, market, provide, offer or sell (a) unbundled software
applications, software tools or other similar technologies (including, without limitation, software as a service, analytics technology or data services) (each, a “Technology Solution”), (b) consulting services that are not
intended to lead to or be a part of a Blueprint Services engagement, implementation contract and/or long-term services contract, or (c) any best practices membership programs or unbundled or bundled physician practice management and other
physician practice management consulting services, in each case referred to in this clause (c) that are substantially similar to, or that are competitive with, ABCO’s best practices membership programs or physician practice management or
other physician practice management consulting services that are offered by ABCO as of the date first written above. For the avoidance of doubt, “unbundled” means on a stand-alone basis, instead of “bundled”, which contemplates
that the Technology Solution is both (i) offered as part of a “packaged”, integrated offering, in conjunction with other Evolent products or services that are not Technology Solutions (and not only services that constitute customary
software, data and end user support-related services), such as the Exclusive TPA Services, and (ii) incidental to the provision of such other Evolent products or services. Notwithstanding any other provision hereof, the foregoing restrictions
in this Section 6.2 shall survive a Change of Control of Evolent for seven (7) years from the date of this Agreement; provided, however, that prior to the seventh (7th) anniversary of the date of this Agreement, the acquiring party in a Change of Control of Evolent shall be not be
subject to the foregoing restrictions with respect to any Technology Solutions or consulting services, in each case, that are unrelated to the Evolent assets acquired. 
 6.3 Non-Solicitation or Hiring: During the Term and for a period of eighteen (18) months thereafter, Evolent shall not solicit or hire any of ABCO’s employees without ABCO’s prior
written consent. 
 7. EXCLUSIVE RESELLER RIGHTS FOR FUTURE PRODUCTS. 

In the event that Evolent creates a discrete or segregable product or service that can be sold to healthcare providers, Evolent
shall notify ABCO in writing of such new offerings (“New Products”). ABCO shall have a period of ninety (90) days (“New Products Evaluation Period”) within which to conduct its evaluation and diligence with
respect to providing such New Products. Evolent shall cooperate with ABCO and provide reasonable assistance and information to ABCO to enable ABCO to conduct its evaluation. Within five (5) business days after the expiration of such New
Products Evaluation Period, ABCO shall notify Evolent in writing whether or not it wishes to have the right to resell such New Products. If ABCO elects to resell such New Products, Evolent and ABCO agree to negotiate in good faith on an exclusive
basis for one hundred twenty (120) days the terms of a reseller agreement, under which ABCO would be the exclusive distributor (in addition to Evolent) of such New Products. 
 8. CONFIDENTIALITY. 
 8.1 Confidential Information:
ABCO acknowledges that in connection with its rights and obligations under this Agreement it may gain access to the Confidential Information of Evolent and its customers and Affiliates. Evolent acknowledges that in connection with its rights

  
 8 

 
and obligations under this Agreement, it may gain access to the Confidential Information of ABCO and its customers and Affiliates. 

8.2 Non-Disclosure: The Receiving Party may disclose the Disclosing Party’s Confidential Information strictly on a
need-to-know basis to only those personnel, including employees of the Receiving Party’s contractors, who require access to the Disclosing Party’s Confidential Information in order to perform or derive benefit from the Services or
otherwise meet its obligations under this Agreement. The Receiving Party agrees: (a) to hold the Disclosing Party’s Confidential Information in strict confidence, using the same degree (but no less than a reasonable degree) of care and
protection that it exercises with its own Confidential Information of a similar nature; (b) not to directly or indirectly disclose or otherwise make available any Confidential Information of the Disclosing Party to a third party; and
(c) not to copy or use the Disclosing Party’s Confidential Information for any purpose other than as necessary to fulfill the Receiving Party’s obligations or exercise its rights under this Agreement. Each Receiving Party is
responsible for ensuring that its employees, agents and contractors strictly abide by the requirements of confidentiality and restrictions on use as provided in this Section 8.2 and shall be liable to the Disclosing Party for any acts or
omissions of its employees, agents and independent contractors relating to the Disclosing Party’s Confidential Information. The Receiving Party is allowed to disclose Confidential Information of the Disclosing Party to the extent required by
Law or by the order or a court of similar judicial or administrative body with jurisdiction, provided that the Receiving Party notifies the Disclosing Party of such required disclosure promptly and in writing and cooperates with the Disclosing
Party, at the Disclosing Party’s reasonable request and expense, in any lawful action to contest or limit the scope of such required disclosure. The provisions of this Section 8 shall survive beyond the expiration or termination of this
Agreement. 
 8.3 Injunctive Relief: The Parties acknowledge and agree that monetary damages may be inadequate to
compensate for a breach of the provisions contained in this Section 8 or other confidentiality provisions of this Agreement. In the event of such breach, the injured Party shall be entitled to seek injunctive relief (without the need to post
bond) and any and all other remedies available at Law or in equity. This Section 8.3 in no way limits the liability or damages that may be assessed against a Party in the event of a breach by the other Party of any of the provisions of this
Section 8. 
 8.4 Residuals: Notwithstanding anything in this Section 8 to the contrary, subject to any
applicable statutory intellectual property rights applicable to patents, trademarks or copyrights, either Party may use “Residuals” for any purpose, including without limitation, for use in development, manufacture, promotion, sale
and maintenance of its products and services; provided, however, that this right to Residuals does not represent a license under any patents, copyrights or trademarks of the Disclosing Party. The term “Residuals” means any
information that is retained in the unaided memories of the Receiving Party’s employees who have had access to the Disclosing Party’s Confidential Information pursuant to the terms of this Agreement. 

9. WARRANTIES. 
 9.1 Authority/No Conflict: ABCO represents and warrants that (a) it has the power and authority to enter into and perform its obligations under this Agreement without conflict with, default
under, or violation of any Law, regulation, or agreement binding upon it, and (b) 

  
 9 

 
this Agreement has been duly authorized by all necessary organizational action, and duly and validly executed and delivered by it, and constitutes its legally valid and binding obligation,
enforceable in accordance with its terms. 
 9.2 Services: ABCO represents, warrants and covenants that the Services
provided under this Agreement will be performed in a professional and workmanlike manner. 
 9.3 Compliance with
Laws/Approvals: Each of ABCO and Evolent shall comply in all material respects with all Laws and regulations applicable to ABCO or Evolent, as applicable, in performing its obligations under this Agreement. To the extent applicable, ABCO shall
be responsible for obtaining all necessary permits, licenses, and consents, including governmental approvals, required of ABCO and its contractors in connection with the performance of its obligations under this Agreement, and Evolent shall be
responsible for obtaining all necessary permits, licenses, and consents, including governmental approvals, required of Evolent and its contractors in connection with the performance of its obligations under this Agreement. 

9.4 Limitations of Warranty: EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, ABCO MAKES NO OTHER WARRANTY OR REPRESENTATION,
ORAL, WRITTEN, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SERVICES, INCLUDING WITHOUT LIMITATION, THEIR QUALITY, PERFORMANCE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, UNINTERRUPTED OR ERROR-FREE OPERATION OR OTHERWISE
HEREUNDER. The disclaimer of warranties and limitations set forth in this Agreement constitute an essential part of this Agreement. 

10. INDEMNIFICATION. 
 10.1 IP Indemnification: ABCO shall defend, indemnify and hold harmless Evolent and its Affiliates (other than ABCO), customers, and their respective officers, directors and employees from and
against any Losses resulting from a claim that the Services provided by ABCO under this Agreement infringes or misappropriates a third party’s intellectual property rights. ABCO shall also use commercially reasonable efforts to modify the
allegedly infringing Services to make it non-infringing, procure a license from the third party claiming infringement to permit Evolent to continue to use the Services, or provide Evolent with functionally equivalent and non-infringing Services.
THIS SECTION 10.1 SETS FORTH ABCO’S SOLE AND EXCLUSIVE LIABILITY, AND EVOLENT’S SOLE AND EXCLUSIVE REMEDY, FOR ALLEGATIONS OR CLAIMS OF INFRINGEMENT OF THIRD PARTY RIGHTS OF ANY KIND ASSERTED AGAINST EVOLENT, ITS AFFILIATES (OTHER THAN
ABCO), CUSTOMERS AND THEIR RESPECTIVE OFFICERS, DIRECTORS AND EMPLOYEES. ABCO shall not be obligated to indemnify Evolent, its Affiliates, customers, and their respective officers, directors and employees for infringement or misappropriation claims
to the extent such claims arise out of use by Evolent or its customers of any of the Services in a manner other than as contemplated by the Parties under this Agreement. 
 10.2 ABCO’s Indemnification: ABCO hereby agrees to indemnify, defend, and hold Evolent and its Affiliates (other than ABCO), and all of their respective directors, officers, members, managers,
partners, employees, agents, successors and assigns, harmless from and against any Losses arising from or related to: (a) the material breach of this Agreement, including any or all SOWs, by ABCO or its personnel (including contractors);
(b) breach of any 

  
 10 

 
of ABCO’s representations, warranties, and covenants in this Agreement; or (c) negligence or willful misconduct by ABCO or its personnel (including contractors). 

10.3 Evolent’s Indemnification: Evolent hereby agrees to indemnify, defend, and hold ABCO and its Affiliates (other than
Evolent), and all of their respective directors, officers, members, managers, partners, employees, agents, successors and assigns, harmless from and against any Losses arising from or related to: (a) the material breach of this Agreement,
including any or all SOWS, by Evolent or its personnel (including contractors); (b) breach of any of Evolent’s representations, warranties and covenants in this Agreement; or (c) negligence or willful misconduct by Evolent or its
personnel (including contractors). 
 10.4 Indemnification Procedure: 

10.4.1 Notice of Claim. Any Party seeking indemnification hereunder (the “Indemnitee”) shall notify the
Party liable for such indemnification (the “Indemnitor”) in writing of any event, omission or occurrence that the Indemnitee has determined has given or could give rise to Losses that are indemnifiable hereunder (such written notice
being hereinafter referred to as a “Notice of Claims”). Such Notice of Claims shall be given promptly after the Indemnitee becomes aware of its own claim or that of a third party; provided that the failure of any Indemnitee to give
notice as provided in this Section 10.4.1 shall not relieve the Indemnitor of its obligations under this Section 10. A Notice of Claims shall specify in reasonable detail the nature and any particulars of the event, omission, or occurrence
giving rise to a right of indemnification. The Indemnitor shall satisfy its obligations hereunder, as the case may be, within thirty (30) days of its receipt of a Notice of Claims. 

10.4.2 Process. With respect to any third party claim, demand, suit, action, or proceeding that is the subject of a Notice
of Claim, the Indemnitor shall, in good faith and at its own expense, defend, contest, or otherwise protect against any such claim, demand, suit, action, or proceeding with legal counsel of its own selection (and reasonably acceptable to the
Indemnitee). The Indemnitee shall have the right, but not the obligation, to participate, at its own expense, in the defense thereof through counsel of its own choice and shall have the right, but not the obligation, to assert any and all cross
claims or counterclaims it may have. So long as the Indemnitor is defending in good faith any such third party claim, demand, suit, action or proceeding, the Indemnitee shall at all times cooperate, at its own expense, in all reasonable ways with,
make its relevant files and records available for inspection and copying by, and make its employees available or otherwise render reasonable assistance to, the Indemnitor. In the event that the Indemnitor fails to timely defend, contest or otherwise
protect against any such third party claim, demand, suit, action, or proceeding, the Indemnitee shall have the right, but not the obligation, to defend, contest, assert cross claims or counterclaims, or otherwise protect against, the same and may
make any compromise or settlement thereof and be entitled to all amounts paid as a result of such third party claim, demand, suit, or action or any compromise or settlement thereof. The Indemnitor will not consent to the entry of any judgment or
enter into any settlement with respect to any such third party claim, demand, suit, action or proceeding without the prior written consent of the Indemnitee, which will not be unreasonably withheld, and provided that no settlement shall require the
Indemnitee to admit liability, or perform or become subject to additional obligations thereunder. 
 11. LIMITS OF LIABILITY.
EXCEPT WITH RESPECT TO OR BREACH BY EITHER PARTY OF THE OTHER PARTY’S CONFIDENTIAL INFORMATION UNDER SECTION 8, 

  
 11 

 
NEITHER EVOLENT NOR ABCO SHALL BE LIABLE FOR, NOR WILL THE MEASURE OF DAMAGES INCLUDE, ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR AMOUNTS INCLUDING WITHOUT LIMITATION
DAMAGES FOR LOSS OF INCOME, PROFITS, OR SAVINGS, LOSS OF DATA, OR COSTS OF PROCUREMENT OF SUBSTITUTE PRODUCTS OR SERVICES, ARISING OUT OF OR RELATING TO ITS PERFORMANCE UNDER THIS AGREEMENT UNDER ANY CAUSE OF ACTION, EVEN IF ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES. IN NO EVENT SHALL EITHER PARTY’S LIABILITY EXCEED THE AMOUNT OF REVENUE ACTUALLY RECEIVED BY ABCO IN THE TWELVE (12) MONTH PERIOD IMMEDIATELY PRECEDING THE EVENTS GIVING RISE TO THE CLAIM. 

12. TERMINATION. 
 12.1 Termination for Cause: Either Party shall have the right to terminate this Agreement in the event the other Party materially violates a material provision of this Agreement and such violation
is not cured or cannot be cured within thirty (30) days after written notice of such material violation. 
 12.2
Survival: The rights and obligations contained in Sections 1, 5 (with respect to Evolent’s payment obligations that may extend beyond the Term), 6.2, 6.3, 8, 9.4, 10, 11, 12.2, 13 and 14 shall survive any termination or expiration of
this Agreement. 
 13. ESCALATION; DISPUTE RESOLUTION. Subject to the terms of Section 13.5, the procedures of this Section 13
will control the resolution of any and all disputes between the Parties including, without limitation, any dispute relating to disputed monies owing or breach of warranty (each, a “Dispute”). The Parties will seek to resolve each
Dispute as follows: 
 13.1 First Level Performance Review: Each Party’s Relationship Manager will meet as often as
will reasonably be required by either Party to review the performance of either Party under this Agreement and to resolve the Dispute. If these representatives are unable to resolve the Dispute within ten (10) business days after the initial
request for a meeting, then the Parties will submit the Dispute to an executive level performance review as provided in Section 13.2 below. 
 13.2 Executive Level Performance Review: Face-to-face negotiations will be conducted by a senior executive officer of each Party (or such other executive as a Party may designate). If these
representatives are unable to resolve the Dispute within five (5) business days after the Parties have commenced negotiations or ten (10) business days have passed since the initial request for a meeting at this level, then the Parties may
jointly engage the services of a third-party mediator. 
 13.3 Arbitration: If the Parties are unable to resolve the
Dispute through the alternative mechanisms described above, the Parties shall submit the Dispute for resolution through binding arbitration, except as otherwise provided in Section 13.5. The Parties agree and consent to such arbitration
proceeding taking place in Wilmington, Delaware, and in accordance with the Commercial Arbitration Rules of the American Arbitration Association, except that discovery may be had in accordance with the Federal Rules of Civil Procedure. The Parties
shall be permitted at least six (6) months from the date of the filing of the Arbitration Demand to conduct discovery. The arbitration proceedings shall be conducted by a panel of three (3) impartial

  
 12 

 
arbitrators, with each Party selecting one (1) of the impartial arbitrators and those two (2) arbitrators then selecting the third impartial arbitrator, all such selections to be made
through the procedures of the American Arbitration Association. At least one (1) arbitrator must be an attorney licensed under the Laws of Pennsylvania and at least one (1) arbitrator (may be the same Person as the Pennsylvania attorney)
must have direct and substantial experience in the industry pertinent to the subject matter of the Dispute. Judgment upon the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof; provided, however, in
rendering its decision, the arbitrators shall be bound by the Laws of the Commonwealth of Pennsylvania (without regard to its conflicts of laws provisions) and by the terms and conditions of this Agreement setting forth the rights and
responsibilities of the Parties. The decision of the arbitration panel shall be accompanied by a written opinion setting forth the factual and legal bases for the award. The arbitrators shall issue such written decision within thirty (30) days
of the conclusion of the arbitration hearing. The arbitrators appointed hereunder shall not have the power to award punitive damages. Service of a petition to confirm the arbitration award may be made by United States mail, postage prepaid, or by
any regularly conducted commercial express mail service, to the attorney for the Party or, if not so represented, to the Party at the address set forth herein, or to the Party’s last known business address. The prevailing Party in any action
related to or arising under this Agreement shall be entitled to reasonable attorneys’ fees and costs. 
 13.3.1 For any
Dispute in which the amount in controversy is at least One Million Dollars ($1,000,000), the following additional procedures apply: 
 (a) a certified court reporter shall transcribe the arbitration hearings; The Parties initially split the cost of the reporter, but such costs shall ultimately be awarded to the Party prevailing in the
arbitration proceeding; and 
 (b) either Party may take an appeal from the final decision by making a written demand within
twenty (20) days of the award. 
 13.3.2 Any such appeal shall be conducted as follows: 

(a) such appeals are limited to issues of Law (i.e., the original award (1) contains material errors of Law such that the original
award is not founded on any appropriate legal basis; (2) is based on factual findings clearly unsupported by the record; or (3) is subject to one or more grounds set forth in Section 10 of the Federal Arbitration Act or 42 Pa. C.S.A.
§7341 for vacating an award); 
 (b) the Person hearing the appeal shall be a former federal judge mutually agreed to by
the Parties or selected through the procedures of the American Arbitration Association. The former judge shall act as the appellate arbitrator; 
 (c) the submissions on appeal are limited to (1) the record of the arbitration, (2) a 30-page brief by the appellant, (3) a 30-page brief by the appellee and (4) a 10-page response by
the appellant. The appellate arbitrator will set the dates for submission of the briefs. Oral argument may be heard at the discretion of the appellate arbitrator; 

  
 13 

 (d) the appellate arbitrator shall render a written decision within sixty (60) days of
the final submission; 
 (e) during the pendency of the arbitration appeal, the Parties agree to suspend any running of the
time to seek enforcement of the original award. The Parties also agree to waive any appeal to state or federal courts based on the grounds set forth in Section 10 of the Federal Arbitration Act for vacating an award and 42 Pa. C.S.A. §
7341; 
 (f) the appellate arbitrator must award costs and attorneys’ fees to the prevailing Party; and 

(g) the decision of the appellate arbitrator shall be final. 
 13.4 Continued Performance: Each Party acknowledges that the timely and complete performance of its obligations pursuant to this Agreement is critical to the business and operations of the other
Party. Accordingly, in the event of a Dispute, each Party shall continue to so perform all of its obligations under this Agreement, in good faith during the resolution of such Dispute unless and until (a) authority to stop doing so is granted
or conferred by a court of competent jurisdiction or (b) this Agreement is terminated in accordance with the provisions hereof. 
 13.5 Equitable Relief: Notwithstanding anything contained in this Agreement to the contrary, the Parties will be entitled to seek injunctive relief, specific performance or other equitable relief
whenever the facts or circumstances would permit a Party to seek equitable relief in a court of competent jurisdiction. Without limiting the generality of the foregoing, (a) Evolent agrees that there would be irreparable harm to ABCO in the
event of any such breach by Evolent of Section 6.2 and ABCO shall be entitled to (i) injunctive relief to prevent breaches of Section 6.2, (ii) specific performance of this Agreement, and (iii) any other remedies provided by
Law or equity, including without limitation an award for damages, and (b) ABCO agrees that there would be irreparable harm to Evolent in the event of any such breach by ABCO of Section 6.1.1, and Evolent shall be entitled to
(i) injunctive relief to prevent breaches of Section 6.1.1, (ii) specific performance of this Agreement, and (iii) any other remedies provided by Law or equity, including without limitation an award for damages. 

14. MISCELLANEOUS PROVISIONS. 
 14.1 Good Faith and Mutual Agreement: Unless otherwise expressly stated in such provision, if a provision in this Agreement calls for the consent of a Party or the mutual agreement of the Parties,
the Parties agree that each will act in good faith, will not unreasonably withhold their consent and that deference shall be given to the other Party’s reasonable business requirements, and the requirements of the Parties’ respective
regulators and internal controls procedures. 
 14.2 Independent Contractor: The relationship of ABCO to Evolent shall at
all times be that of an independent contractor. Nothing in this Agreement shall be construed to create any partnership, association, joint venture, or employment between the Parties. Each Party shall have the sole and exclusive control over the
labor and employee relations policies and policies relating 

  
 14 

 
to wages, hours, working conditions, benefits, or other conditions of its personnel and shall be responsible and liable for the acts and omissions of its employees, agents and contractors.

 14.3 Assignability: Evolent has entered into this Agreement because of the expertise of ABCO, and ABCO understands
that the obligations of ABCO are personal to ABCO and may not be assigned to any other company, partnership or individual without the express written consent of Evolent; provided, however, that no consent shall be required if an assignment is made
in connection with a sale of all or substantially all of ABCO’s assets or stock, or in connection with a merger or Change of Control. Evolent may assign this Agreement (including the licenses granted pursuant to this Agreement) to any Affiliate
of Evolent as part of an internal reorganization or in connection with a sale of substantially all of its assets or stock, or in connection with a merger or Change of Control. 
 14.4 Governing Law and Jurisdiction: This Agreement shall be governed by and construed and enforced in accordance with the Laws of the Commonwealth of Pennsylvania, without regard to that state or
any other state’s conflicts of law rules. Each Party irrevocably consents to the personal jurisdiction of the state and federal courts located in Wilmington, Delaware for any suit or action arising from or related to this Agreement. 

14.5 Force Majeure: Neither Party shall be deemed in default of this Agreement to the extent that performance of their obligations
or attempts to cure any breach are delayed or prevented by reason of any act of God, fire, natural disaster, accident, act of government, or any other cause beyond the control of such Party, provided that such Party gives the other Party written
notice thereof promptly and, in any event, within fifteen (15) days of discovery thereof, and uses its commercially reasonable efforts to cure any such breach. 
 14.6 Entire Agreement: This Agreement and its exhibits, schedules, and attachments constitute the entire understanding between the Parties with respect to the subject matter hereof and supersede
all prior written or oral representations with respect to the subject matter hereof. This Agreement may not be modified, amended, or otherwise changed in any manner except by a written instrument executed by the Party against whom enforcement is
sought. 
 14.7 Cumulative Remedies: Except as expressly provided in this Agreement, (a) remedies for breach are
cumulative and may be exercised separately or concurrently, (b) the exercise of one remedy is not an election of that remedy to the exclusion of others, and (c) the provision for any remedy in this Agreement shall not affect remedies
otherwise available at Law or in equity. 
 14.8 No Third Party Beneficiaries: The Parties do not intend that this
Agreement creates any right or cause of action in or on behalf of any Person other than Evolent and ABCO. 
 14.9
Headings: Section headings have been included in this Agreement merely for convenience of reference. They are not to be considered part of, or to be used in interpreting this Agreement. 

14.10 Binding Effect: The covenants and conditions contained herein will apply to and bind the successors, representatives, and
permitted assigns of the Parties. 
 14.11 Expenses: Each Party shall be responsible for its own legal, accounting and
other transaction costs relating to the transactions contemplated in this Agreement. 

  
 15 

 14.12 Notices: All notices required to be given hereunder shall be in writing and
given hereunder, as elected by the Party giving notice, as follows: (a) by personal delivery, (b) sent by overnight courier with confirmation of receipt, or (c) dispatched by certified or registered mail, return receipt requested,
postage prepaid, addressed to the Parties as follows. 
  

			
		
	    If to Evolent:	  	 Evolent, Inc.
 800 N. Glebe
Road, Suite 500
 Arlington, VA 22203

Attention: President

		
		  	 Morgan Lewis & Bockius, LLP
 225 Franklin Street
 Boston, MA 02110
 Attention: Mark B. Stein, Esq.
 Fax No.: (617) 341-7701

		
	    If to ABCO:	  	 The Advisory Board Company

2445 M St. NW
 Washington, DC 20037

Attention: General Counsel

 Notice shall be deemed given (a) on the date of receipt if delivered personally; (b) on the business day
following delivery of such notice to the overnight courier; or (c) three (3) business days after deposit in the mail in accordance with the foregoing. Either Party may change the address to which to send notices by notifying the other
Party of such change of address in writing in accordance with the foregoing. 
 14.13 Press Releases: No press releases
or other public announcements concerning the transactions contemplated by this Agreement shall be made by ABCO or Evolent without the prior written consent of both Parties; provided, however, that nothing herein shall prevent a Party from supplying
such information or making statements as required by governmental authority or in order for a Party to satisfy its legal obligations (prompt notice of which shall in any such case be given to the other Party). 

14.14 Severability: Any terms or provisions of this Agreement that shall prove to be invalid, void or illegal shall in no way
affect, impair, or invalidate any other term or provision herein and such remaining terms and provisions shall remain in full force and effect provided that its general purposes are still reasonably capable of being effected. All such terms or
provisions which are determined by a court of competent jurisdiction or other dispute resolution proceeding to be invalid, void or illegal shall be construed and limited so as to allow the maximum effect permissible by Law. 

14.15 Waiver: The waiver by either Party to this Agreement of any one or more defaults, if any, on the part of the other, shall
not be construed to operate as a waiver of any other or future defaults under the same or different terms, conditions or covenants contained in this Agreement. 

  
 16 

 IN WITNESS WHEREOF, the Parties have executed this Agreement effective as of the date
first written above. 
  

									
	THE ADVISORY BOARD COMPANY	 		 	EVOLENT HEALTH, INC.
			
	            /s/  Evan Farber	 		 	 
					
	By:	 	    Evan Farber	 		 	By:	 	 
					
	Its:	 	    General Counsel	 		 	Its:	 	 

 [Signature Page to Amended and Restated Services, Reseller and Non-Competition Agreement] 

  
 17 

 IN WITNESS WHEREOF, the Parties have executed this Agreement effective as of the date
first written above. 
  

									
	THE ADVISORY BOARD COMPANY	 		 	EVOLENT HEALTH, INC.
			
	 	 		 	            /s/  Frank Williams
					
	By:	 	 	 		 	By:	 	    Frank Williams
					
	Its:	 	 	 		 	Its:	 	    CEO

 [Signature Page to Amended and Restated Services, Reseller and Non-Competition Agreement]EX-10.17

 Exhibit 10.17 

FIRST AMENDMENT TO THE 

AMENDED AND RESTATED SERVICES, RESELLER 

AND NON-COMPETITION AGREEMENT 

This First Amendment (the “Amendment”) to the Amended and Restated Services, Reseller and Non-Competition Agreement (the
“Agreement”) is made and entered into this 1st day of May, 2015 (the “Amendment Effective Date”) by and between The Advisory Board
Company, a Delaware Corporation (“ABCO”) and Evolent Health LLC, a Delaware Limited Liability Company and successor- in- interest to Evolent Health, Inc. (“Evolent”) (each a
“Party” and collectively the “Parties”). 

WHEREAS, the Parties entered into the Agreement effective June 27, 2013; and 

WHEREAS, the Parties have continued to explore ways to improve the efficiency of their relationship and
their respective abilities to provide services to hospitals and health systems; and 
 WHEREAS, as a
result of the foregoing efforts, the Parties have agreed to amend the Agreement. 
 NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 

A. Amendment. As of the Amendment Effective Date, this Amendment hereby amends the Agreement as follows: 

 

	 	1.	Section 2.2.1 of the Agreement (Applicable Services) shall be amended to add new subsections (e), (f), (g), (h) and (i) as follows: 

(e) Services to optimize or implement an Evolent Client’s electronic medical record (EMR) system, including EMR optimization
services to be provided in connection with the implementation of Identifi, except (1) in specific circumstances where such EMR optimization and implementation services would be de minimis and highly integrated with other
services being provided by Evolent that it would not be commercially or reasonably practicable for an individual to provide such EMR optimization or implementation who is not also providing other services to the Evolent Client and
(2) provided that Evolent informs ABCO during the meetings described in Section 13.6 or otherwise of the circumstances described in immediately preceding clause (1) such that ABCO can in good faith evaluate
whether Evolent is complying with the intent and purpose of ABCO’s right of first offer in this Section 2.2.1(e); 

(f) Clinical documentation improvement services; provided, however, that such services are not related to, or a part of, a broader set of
value-based care services such as, but not limited to, risk adjustment documentation (e.g., RAF services); 
 (g) Online patient scheduling
systems; 
 (h) Crimson Market Advantage (“CMA”) functionality; and 

  
 - 1 - 

 (i) Referral management technology products; provided, however, that Evolent shall only be
obligated to provide ABCO the right of first offer pursuant to this Section 2.2.1 if ABCO is willing to integrate the referral management functionality into Identifi such that ABCO’s referral management technology product can access
or receive Identifi clinical data and that, following the first anniversary of the Amendment Effective Date and if there is demand from at least five (5) Evolent Clients, Identifi and ABCO’s referral management functionality can be
accessed with a single sign-on and the referral management technology is capable of allowing a user to transmit a patient referral with the patient’s clinical data to a health care provider through Identifi, it being agreed that
(i) Evolent shall provide ABCO with such support, cooperation, and assistance as are reasonably necessary to enable the integration of Identifi and ABCO’s referral management technology as described in this Section 2.2.1(i) and
(ii) ABCO and Evolent shall in good faith meet periodically at mutually agreed upon times during the Term to discuss Evolent’s perspectives and input on such other features and functionality that may be reasonably necessary to be included
in ABCO’s referral management technology to address market needs. 
  

	 	2.	A new Section 2.2.3 shall be added to the Agreement as follows: 

 In the event that
ABCO exercises its right of first offer and performs a First Offer Service for an Evolent Client, ABCO shall be prohibited from selling or offering to that Evolent Client any new ABCO Restricted Products or Services to such Evolent Client that were
not already in an Active ABCO Sales Process. For purposes of this Agreement, “Active ABCO Sales Process,” means, with respect to any Person as of the date on which Evolent refers the Person to ABCO for certain ABCO products or
services or the other relevant time, a Person who (a) is purchasing such ABCO products or services as of such date or (b) either (i) has purchased such ABCO products or services from ABCO prior to such date or (ii) is engaged in
active discussions with ABCO as of such date about (A) acquiring such products or services from ABCO, or (B) addressing the issues that such products or services are primarily intended to address. 

 

	 	3.	Section 2.3 of the Agreement (Failure to Execute a Service Agreement for the VBC Innovation Center) is hereby deleted in its entirety. 

 

	 	4.	Section 2.4 (Reservation of Rights) and Section 2.5 (Designation of Relationship Managers) of the Agreement are hereby renumbered as Sections 2.3 and 2.4 respectively.

  

	 	5.	Section 3 (Fees; Payment Terms; Shortfall) of the Agreement shall be deleted in its entirety and replaced with the following: 

 

	 	3.	FEES; PAYMENT TERMS. 

 Subject to the terms of this Agreement, Evolent shall pay ABCO
the applicable fees for the Services performed by ABCO pursuant to a Statement of Work as set forth in the Statement of Work, this Agreement, or as otherwise agreed in a separate writing signed by the Parties. 

  
 - 2 - 

	 	6.	Section 4 (Term and Renewal) of the Agreement shall be deleted in its entirety and replaced with the following: 

  

	 	4.	TERM AND RENEWAL. The initial term of this Agreement shall commence on the Effective Date and unless sooner terminated in accordance with the terms hereof, shall continue through June 30, 2017
(“Initial Term”). Thereafter, this Agreement shall automatically be renewed for another five-year term (“Renewal Term;” the Initial Term together with each Renewal Term, the “Term”). At any time
during the Initial Term or a Renewal Term, either Party may terminate this Agreement without cause upon ninety (90) days’ prior written notice to the other Party. 

 

	 	7.	Section 5 (Referral Fees, Solicitation and Competition and Post-Closing Services) shall be deleted in its entirety and replaced with the following: 

 

	 	5.	REFERRALS. 

  

	 	5.1	Referrals by Evolent to ABCO for Products and Services that Evolent is Unable to Provide: In addition to the services to be provided by ABCO described in Section 2.1 and any services that may be
provided pursuant to referrals or partnering arrangements contemplated by Section 5.2 and subject to ABCO’s right of first refusal in Section 2.2, the Parties acknowledge that there may arise situations where, in order
to meet the requirements of a Person with whom Evolent may have had dealings or interactions but who is not an Evolent Client (a “Non-Evolent Client”), it may be necessary or desirable for Evolent to arrange for the provision of
technology solutions or services that Evolent is restricted from providing under the terms of this Agreement. In such situations, the Parties acknowledge that it may be advantageous to Evolent for ABCO to provide such technology solutions or
services to the Non-Evolent Client. Any such technology solutions or services provided by ABCO by mutual agreement of the Parties under this Section 5.1 will (unless otherwise agreed by the Parties in writing) be subject to the pricing,
referral and commission payment, and other terms as follows: 

  

	 	5.1.1	Client Contract Relationship; Pricing Terms. At the option of Evolent, any agreement pursuant to which ABCO may provide technology solutions or services to a Non-Evolent Client under this Section 5.1
may be through a contract between Evolent and the Non-Evolent Client, where ABCO acts as a subcontractor or vendor to Evolent (subject to any third party restrictions imposed on ABCO (e.g., third party software license terms)), or through a contract
directly between ABCO and the Non-Evolent Client. ABCO pricing of the technology solutions or services to be provided to a Non-Evolent Client pursuant to this Section 5.1 will be at (i) a [***] percent ([***]%) discount from the
standard ABCO pricing calculator for technology product offerings, (ii) [***] percent ([***]%) discount for consulting services, and (iii) [***] percent ([***]%) discount for best practices research services. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 3 - 

	 	5.1.2	Payment. Where ABCO provides technology solutions or services to a Non-Evolent Client pursuant to this Section 5.1 as a subcontractor or vendor to Evolent, payment shall be made by Evolent to ABCO
based on ABCO’s delivery of services pursuant to the applicable subcontract or Statement of Work. Where ABCO provides technology solutions or services to a Non-Evolent Client pursuant to a contract directly between ABCO and the Non-Evolent
Client, payment shall be made by the Non-Evolent Client pursuant to the terms of such contract unless otherwise agreed by Evolent, the Non-Evolent Client, and ABCO in a separate writing. 

 

	 	5.1.3	Evolent Referral Fee. For services contracted during the Term to be provided by ABCO pursuant to this Section 5.1, ABCO will pay Evolent a one-time sales referral fee for technology solutions or
services provided by ABCO to a Non-Evolent Client pursuant to this Section 5.1 in the amount of [***] percent ([***]%) of the first year fees received by ABCO for the provision of such technology solutions or services to such Non-Evolent
Client. In the event that ABCO is providing such technology solutions or services as a subcontractor or vendor to Evolent, payment of the referral fee under this Section 5.1.3 shall coincide with payment made by Evolent to ABCO pursuant
to Section 5.1.2. In the event that ABCO is providing such technology solutions or services pursuant to a contract directly between ABCO and the Non-Evolent Client, payment of the referral fee under this Section 5.1.3 shall
be made promptly following the receipt by ABCO of payment from the Non-Evolent Client pursuant to the terms of such contract unless otherwise agreed by Evolent, the Non-Evolent Client, and ABCO in a separate writing. 

 

	 	5.2	 Referrals by Evolent to ABCO for Services that Evolent May be Permitted to Provide in Certain Circumstances: In addition to the services to be
provided by ABCO described in Section 2.1 and any services that may be provided pursuant to referrals or partnering arrangements contemplated by Section 5.1 and subject to ABCO’s right of first refusal in
Section 2.2, the Parties agree that there may be opportunities for ABCO to provide additional technology solutions or services to or on behalf of Evolent in connection with services Evolent has contracted to provide to Evolent Clients.
Any such technology solutions or services provided by ABCO under this Section 5.2 to Evolent Clients (a) referred to ABCO in writing and (b) who were not in an Active ABCO Sales Process, will be subject to the pricing, referral
and commission payment, and other terms as follows (for the avoidance of doubt, if an Evolent Client was in an Active ABCO Sales Process at the time of Evolent’s referral, Evolent and ABCO will have no obligation to work together with respect
to 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 4 - 

	 	
such Evolent Client, provided that the Relationship Managers shall discuss and determine if there are opportunities for Evolent and ABCO to work together with respect to such Evolent Client):

  

	 	5.2.1	Client Contract Relationship; Pricing Terms. At the option of Evolent, any agreement pursuant to which ABCO may provide technology solutions or services to an Evolent Client under Section 5.2 may be
through a contract between Evolent and the Evolent Client, where ABCO acts as a subcontractor or vendor to Evolent (subject to any third party restrictions imposed on ABCO (e.g., third party software license terms)), or through a contract directly
between ABCO and the Evolent Client. ABCO pricing of the technology solutions or services to be provided to an Evolent Client pursuant to this Section 5.2 will be at a [***] percent ([***]%) discount from the standard ABCO pricing
calculator unless otherwise agreed by Evolent, the Evolent Client, and ABCO in a separate writing. 

  

	 	5.2.2	Payment. Where ABCO provides technology solutions or services to an Evolent Client pursuant to this Section 5.2 where ABCO acts as a subcontractor or vendor to Evolent, payment shall be made by
Evolent to ABCO based on ABCO’s delivery of services pursuant to the applicable subcontract or Statement of Work. Where ABCO provides technology solutions or services to an Evolent Client pursuant to a contract directly between ABCO and the
Evolent Client, payment shall be made by the Evolent Client pursuant to the terms of such contract unless otherwise agreed by Evolent, the Evolent Client, and ABCO in a separate writing. 

 

	 	5.2.3	Evolent Referral Fee. For services contracted during the Term to be provided by ABCO pursuant to this Section 5.2, ABCO will pay Evolent a one-time sales referral fee for technology solutions or
services provided by ABCO to an Evolent Client pursuant to this Section 5.2 unless the Evolent Client was in an Active ABCO Sales Process at the time of the referral in the amount of [***] percent ([***]%) of the first year fees received
by ABCO for the provision of such technology solutions or services to such Evolent Client. In the event that ABCO is providing such technology solutions or services as a subcontractor or vendor to Evolent, payment of the referral fee under this
Section 5.2.3 shall coincide with payment made by Evolent to ABCO pursuant to Section 5.2.2. In the event that ABCO is providing such technology solutions or services pursuant to a contract directly between ABCO and the
Evolent Client, payment of the referral fee under this Section 5.2.3 shall be made promptly following the receipt by ABCO of payment from the Evolent Client pursuant to the terms of such contract unless otherwise agreed by Evolent, the
Evolent Client, and ABCO in a separate writing. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 5 - 

	 	5.2.4	Evolent Ongoing Commission. In addition to the referral fee payment to be made pursuant to Section 5.2.3, unless the Evolent Client was in an Active ABCO Sales Process at
the time of the referral, ABCO will pay Evolent an annual sales commission fee for technology solutions or services provided by ABCO to an Evolent Client pursuant to Section 5.2. The amount of such fee shall be equal to
(i) [***] percent ([***]%) of the second-year fees received by ABCO for the provision of such technology solutions or services and (ii) [***] percent ([***]%) of the annual fees received by ABCO for the provision of such technology
solutions or services in each subsequent year in which ABCO provides such technology solutions or services. In the event that ABCO is providing such technology solutions or services as a subcontractor or vendor to Evolent, payment of the sales
commission fee under this Section 5.2.4 shall coincide with payment made by Evolent to ABCO pursuant to Section 5.2.2. In the event that ABCO is providing such technology solutions or services pursuant to a contract
directly between ABCO and the Evolent Client, payment of the referral fee under this Section 5.2.4 shall be made promptly following the receipt by ABCO of payment from the Evolent Client pursuant to the terms of such contract unless
otherwise agreed by Evolent, the Evolent Client, and ABCO in a separate writing. 

  

	 	5.3	 Referrals by ABCO to Evolent: The Parties agree to collaboratively develop a list of twenty (20) client target opportunities, associated
product offerings, and joint sales strategies on an annual basis (“Co-Marketed Targets”) and determine a strategy for one or both Parties to seek to arrange a demonstration of the joint capabilities to the Co-Marketed Targets. In
the event ABCO refers an organization to Evolent, whether such organization is a Co-Marketed Target or not (a “Potential Referral”), and within eighteen (18) months of such referral, Evolent signs the Potential Referral to an
implementation and/or long-term services contract (an “ABCO Referred Organization”), Evolent shall pay ABCO the fees set out in Sections 5.3.1 and 5.3.2. To qualify as an ABCO Referred Organization, ABCO must
interact with the Potential Referral, Evolent must not reasonably demonstrate to ABCO within five (5) business days after its receipt of ABCO’s referral that the Potential Referral actively evaluated Evolent’s capabilities within the
ninety (90) days preceding the date of the referral and the Potential Referral must actively evaluate Evolent during the eighteen (18) months following ABCO’s referral, and, if the Potential Referral was not a Co-Marketed Target,
ABCO’s referral and other activities must have been a contributing factor to Evolent entering into an implementation and/or long-term services contract with that Person (e.g., a Potential Referral that does not advance but fifteen
(15) months later issues an RFP for services would not count as a Potential Referral if ABCO’s activities did not contribute to the Potential Referral issuing the RFP to Evolent). ABCO and Evolent may mutually agree to waive the
requirement for the Potential Referral to have been evaluating Evolent during the ninety (90) day period prior to the referral. ABCO can refer no more than twenty (20) 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 6 - 

	 	
Potential Referrals to Evolent in any twelve (12) month period during the Term, it being agreed that ABCO can remove Persons from the list of Potential Referrals who may no longer be
interested in engaging in discussions for Evolent services and add new Persons to the list as replacements. 

  

	 	5.3.1	Co-Marketing Fee. For referrals made by ABCO to Evolent during the Term, Evolent will pay ABCO a one-time sales referral fee for services provided by Evolent to a Co-Marketed Target pursuant to this
Section 5.3 in the amount of [***] percent ([***]%) of the first year fees paid to Evolent within thirty (30) days after the end of the first year of the contract between Evolent and the Co-Marketed Target. 

 

	 	5.3.2	 Bundled Product Requirement. Evolent must include in its service offering to and contracts with ABCO Referred Organizations the ABCO
Network Development Technology Products (which are ABCO’s Crimson Market Advantage, Crimson Medical Referrals, and HealthPost technology products (as such products may be renamed, supplemented, or modified by ABCO from time to time)) for the
greater of two (2) years and the term of the agreement between Evolent and the ABCO Referred Organization. Evolent may price the ABCO Network Development Technology Products in its discretion, provided that, if Evolent sets a price for the ABCO
Network Development Technology Products in a proposal or contract with the ABCO Referred Organization, the price may not be less than [***] percent ([***]%) of ABCO’s standard ABCO pricing calculator for such ABCO Network
Development Technology Products (such pricing, the “Evolent Pricing for the Bundled Products”). Evolent shall pay ABCO the Evolent Pricing for the Bundled Products as follows: (i) the implementation fee for the ABCO Network
Development Technology Products shall be paid within sixty (60) days after Evolent enters into the contract with the ABCO Referred Organization and (ii) the annual membership/subscription fee shall be paid in quarterly installments within
thirty (30) days after the commencement of each three-month period during the term of Evolent’s contract with the ABCO Referred Organization (collectively, the fees set forth in clauses (i) and (ii) above shall be
referred to herein as the “EPBP Fees”). ABCO shall calculate the payments made by Evolent in respect of the EPBP Fees within sixty (60) days after the end of the fourth
(4th) consecutive year of Evolent’s contract with its client (or within sixty (60) days after the end of the term of such contract, if fewer than four (4) consecutive years
remained in the term of such contract after the prior calculation), and, if the average annual payment to ABCO over such period was less than $[***] for such client, Evolent shall pay to ABCO the amount of such shortfall such that ABCO is paid at
least an average of $[***] for each such year (i.e., $[***] over a four-year period) for each ABCO Referred Organization (it being acknowledged 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 7 - 

	 	
and agreed that for each contract with an ABCO Referred Organization that has a term of less than four (4) years, ABCO shall calculate the payments made by Evolent in respect of the EPBP
Fees within sixty (60) days after the term of such contract, and, if the average annual payment to ABCO over the term of such contract was less than $[***] for each year of such contract, Evolent shall pay to ABCO the amount of such shortfall
such that ABCO is paid at least an average of $[***] for each year of such contract). For the avoidance of doubt, the fees due to ABCO from an ABCO Referred Organization shall continue after the Term until the later of (x) the last day that
ABCO provides ABCO Network Development Products to the ABCO Referred Organization and (y) the earlier of the third (3rd) anniversary of the last day of the Term or last day of the term
of the agreement between Evolent and the ABCO Referred Organization, provided that ABCO referred the ABCO Referred Organization to Evolent during the Term (it being acknowledged that ABCO shall never be required to provide services without receiving
the agreed upon payment for those services). When calculating payments of EPBP Fees and any shortfalls pursuant to this Section 5.3.2, ABCO shall in good faith make adjustments to amounts that would have been payable to ABCO on account of contracts
with ABCO Referred Organizations that may have been terminated by the ABCO Referred Organization with the first six (6) months of the term of such contract. 

  

	 	5.3.3	Evolent Protections for ABCO Referred Organization Bundled Product Requirement. If ABCO introduces Evolent to an ABCO Referred Organization, the EPBP Fees for that ABCO Referred Organization shall
be capped at [***] percent ([***]%) of the total fees payable to Evolent by the ABCO Referred Organization for both implementation and long-term contract scope; provided, however, that ABCO shall never receive less than [***] percent ([***]%) of
ABCO standard pricing for the ABCO Network Development Technology Products deployed by Evolent at an ABCO Referred Organization (i.e., Evolent may be permitted to deploy fewer ABCO Network Development Technology Products to ensure that those
products do not exceed, in aggregate, more than [***] percent ([***]%) of the total fees payable to Evolent by the ABCO Referred Organization). 

  

	 	8.	Section 6.2 of the Agreement shall be deleted in its entirety and replaced with the following: 

  

	 	6.2	 Evolent shall not, until the earlier of (x) ABCO’s ceasing to be an equity holder of Evolent (unless ABCO ceases to be an equity holder of
Evolent as a result of a (a) Change of Control of Evolent or (b) recapitalization or reorganization of Evolent but ABCO continues to hold equity in an Affiliate of Evolent as a result of such recapitalization or reorganization) or
(y) June 27, 2020 (except for Sections 6.2(e)(i)-(iv), which shall terminate on the last day of the Term if ABCO terminates this Agreement without cause pursuant to Section 4; otherwise,
the restrictions in Section 6.2(e)(i)-(iv) shall continue until the later of (x) the four (4) year anniversary of the Amendment Effective Date or (y) the last day of the Term if this Agreement is terminated by
Evolent; provided, however, that under no circumstances shall Evolent 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 8 - 

 
promote, market, provide, offer or sell any of the products or services described in Section 6.2(e) unbundled from or not integrated with Identifi through June 27, 2020),
promote, market, provide, offer or sell: 
 (a) unbundled software applications, software tools or other similar technologies (including,
without limitation, software as a service, or analytics technology) that are competitive in any material respect with any ABCO products or services at the time the Evolent product or service is promoted, marketed, or sold. For the avoidance of
doubt, Evolent clinical programs, clinical processes and rules/content are not considered technology. For purposes of this Section 6.2(a), unbundled means that more than fifty percent (50%) of the aggregate revenue attributable to
the Evolent Client during the term of the contract are for software applications, software tools or other similar technologies (including, for the avoidance of doubt, Identifi) and software and technology support and maintenance (including user
support or any other services support that are customarily associated with the implementation or ongoing management or oversight of technology products) regardless of the fee amounts set forth in Evolent’s agreement(s) with the Evolent Client;

 (b) Blueprint or non-Blueprint consulting services or products that are competitive in any material respect with any ABCO products or
services at the time the Evolent product or service is promoted, marketed, or sold, unless such consulting services are reasonably expected to lead to a long-term services contract or be part of a Blueprint Services engagement;
“Blueprint” and “Blueprint Services” are defined as a consulting engagement pursuant to which Evolent has been engaged by a Person to assess what would be required for the Person to (a) acquire or develop
health plan capabilities, or (b) expand the Person’s health plan capabilities, or (c) initiate or expand the Person’s ability to establish value-based care contracting arrangements (i.e., contracts that contemplate a
performance-based gain share payment or a set payment to a health care provider organization for each enrolled person assigned to such provider, for a period of time, for the provision of specified care). Evolent shall only permitted to provide
consulting services that Evolent is permitted to provide pursuant to this Section 6.2 and Blueprint Services for a Person and its Affiliates for up to six (6) consecutive calendar quarters on an uninterrupted basis (i.e., the
services cannot commence, cease, and recommence during that period; Evolent should have an ongoing consulting relationship with that Person or its Affiliates during that period) and Evolent thereafter must cease charging fees for any services unless
the Person or one or more of its Affiliates entered into an implementation and/or long-term services contract with Evolent (i.e., Evolent can continue providing services to such Person and its Affiliates after such six (6) calendar-quarter
period, but cannot be compensated for such services unless and until the Person enters into an implementation and/or long-term services contract with Evolent); 

  
 - 9 - 

 (c) any best practices membership programs or physician practice management or bundled or
unbundled physician practice management and other physician practice management consulting services, in each case referred that are substantially similar to, or that are competitive with, (i) ABCO’s best practices membership programs or
(ii) physician practice management or other physician practice management consulting services that were offered by ABCO as of August 2013; or 

(d) any services which are competitive in any material respect with any ABCO products or services at the time the Evolent service is promoted,
marketed, or sold, where (i) the Evolent client will (based on reasonable documented expectations with the Evolent client at the time the contract is signed by the client) generate Evolent revenue less than $1.75 million annually, on average,
across the life of the initial contract inclusive of the implementation and long-term contract fees, (ii) the average annual revenue from all long-term services contract customers signed after June 27, 2013, inclusive of implementation and
long-term services revenue, is less than $5.0 million each year, and (iii) Evolent is not required to have more than six and three quarter (6.75) Dedicated FTEs per year, on average, across the life of the client contract inclusive of the
implementation and long-term contract scopes. The contract length shall begin on the date of the first implementation and/or long-term services contract and extend through the expiration of such contract. For purposes of this provision,
“Dedicated FTEs” are defined as Evolent personnel who are either directly tracking time to the Evolent Client or are allocated to the client from the Evolent national support model during the project pricing process. For the
avoidance of doubt, Evolent general and administrative full-time employees will not be allocated to the Evolent Client or considered Dedicated FTEs. Both national support model and general and administrative cost categories and related full-time
employees shall be defined as they existed in the Evolent WorkDay ERP system as of January 1, 2015 as described on Exhibit A hereto. For purposes of this section any long-term-services contracts with non-provider customers (i.e.,
employers) that are linked to a health system Evolent client shall not count as a separate Evolent Client for purposes of calculating Dedicated FTEs if Evolent is serving the non-provider customer in coordination with the Evolent Client where
coordination means that Evolent is providing the non-provider customer long-term contract services similar to those provided to the Evolent Client. 

(e) Evolent also agrees not to, directly or indirectly, develop, promote, market, provide, offer or sell products with functionality
substantially similar to (i.e., redundant in any material respect) the following except to the extent permitted by and subject to Section 2.2.1: 

(i) Services to optimize or implement a Person’s electronic medical record (EMR) system unless (although still
subject to Section 2.2.1) (i) such services are being provided for Evolent Clients in connection with the implementation or optimization of Identifi or (ii) such services are being provided to a potential Evolent Client as part
of a diagnostic or proof of concept to demonstrate to the potential Evolent Client how Identifi would work with and/or optimize the Person’s EMR and Evolent’s ability to implement Identifi; 

  
 - 10 - 

 (ii) ABCO’s online scheduling system (referred to as HealthPost as of the
date of Amendment Effective Date) as it existed as of the Amendment Effective Date; 
 (iii) ABCO’s market
referrals product (referred to as CMA as of the date of the Amendment Effective Date) as it existed as of the Amendment Effective Date, provided the Evolent is allowed to continue sharing data with physicians in the manner in which Evolent is
providing data to Evolent Clients as of the Amendment Effective Date as described on Exhibit B hereto; and 

(iv) ABCO’s referral management technology product (referred to as Crimson Referral Management as of the Amendment
Effective Date) as it existed as of the date of the Amendment Effective Date except as expressly permitted in the last sentence of Section 2.2.1(i) and, if ABCO is unwilling to integrate its referral management functionality with
Identifi as described in Section 2.2.1(i) or if Section 2.2.1(i) is no longer in effect, then Evolent would be enabled to directly provide referral management functionality through Identifi but would not be permitted to
access those services from a third party (i.e., Evolent would not be permitted to license or integrate any third party’s referral management functionality into Identifi or other Evolent technology products or services. 

Notwithstanding any other provision hereof, the foregoing restrictions in this Section 6.2 shall survive a Change of
Control of Evolent through June 27, 2020; provided, however, that prior to June 27, 2020, the acquiring party in a Change of Control of Evolent shall be not be subject to the foregoing restrictions with respect to any technology solutions
or consulting services, in each case, that are unrelated to the Evolent assets acquired. In addition, (1) the restrictions in this Section 6.2 shall not apply to the type and scope of services proposed to be offered to the
Persons described in the letter from Evolent to ABCO dated April     , 2015, and (2) during the period between the last day of the Term and the expiration of the periods described in the first
paragraph of this Section 6.2, ABCO shall in good faith at Evolent’s request discuss with Evolent the provision by ABCO of any products or services that Evolent is not permitted or is otherwise unable to provide pursuant to this
Section 6.2 to Evolent and/or Evolent clients, with the terms of the provision of such products or services to be the subject of a separate written agreement between ABCO and Evolent. 

 

	 	9.	Without limiting Section 11 of the Agreement (Limits of Liability), the limitations of liability in Section 11 of the Agreement shall not apply to a breach of Sections 2 or 6
of the Agreement or affect Sections 12.3, 12.4, or 13.5 of the Agreement. If it is determined that a Party has breached one or more material terms of Section 6.1.1 or 6.2 or the Agreement, as the case may be, the
non-breaching Party shall be awarded 

  
 - 11 - 

	 	
pursuant to Section 13.3 of the Agreement damages as determined by an arbitrator including, but not limited to, lost profits. In addition, Evolent’s payment obligations (if
any) that may arise pursuant to Sections 12.3 or 12.3 as a result of Evolent conduct or activities prior to the last day of the Term shall survive the expiration or earlier termination of the Agreement. 

 

	 	10.	New Sections 12.3, 12.4, and 12.5 shall be added to the Agreement as follows: 

  

	 	12.3	Payments Upon Early Termination: 

 In the event that an ABCO client (i) terminates
its agreement with ABCO (other than as a result of a material uncured breach by ABCO of such agreement) prior to the end of the then-current term of such agreement and (ii) within six (6) months of such termination begins using services or
technology from Evolent that made such ABCO products or services redundant in a material respect (the “Overlapping Products/Services”), then Evolent shall pay to ABCO [***] percent ([***]%) of the remaining fees that would have been
paid to ABCO by the ABCO client for the Overlapping Products/Services during the remainder of the contract, in the event that such contract is terminated prior to the end of a contract (each such payment, an “Early Termination
Payment”). 
 Each Early Termination Payment shall be due and payable in accordance with the payment terms of the terminated
agreement, provided that the first payment of such Early Termination Payment also shall include all of the payments that would have been paid during the period beginning on the date of termination and ending on the date upon which such first
payment is made. 
  

	 	12.4	Payments Upon Non-Renewal: 

 In the event that an ABCO client (i) fails to renew
its agreement with ABCO at the end of the then-current term of such agreement and (ii) within six (6) months of such termination begins using Overlapping Products/Services and (iii) the Overlapping Products/Services were not incidental to
the non-renewal decision by the ABCO Client, then Evolent shall make the following payments to ABCO (each such payment, a “Non-Renewal Payment”): 
  

	 	12.4.1	[***] percent ([***]%) of the fees that would have been paid to ABCO by the ABCO client during the first contract year of the renewal period if such contract had been renewed on the same terms; 

 

	 	12.4.2	[***] percent ([***]%) of the fees that would have been paid to ABCO by the ABCO client during the second contract year of the renewal period as if such contract had been renewed on the same terms; 

 

	 	12.4.3	[***] percent ([***]%) of the fees that would have been paid to ABCO by the ABCO client during the third contract year of the renewal period as if such contract had been renewed on the same terms; and 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 12 - 

	 	12.4.4	[***] ([***]%) of the fees that would have been paid to ABCO by the ABCO client during the fourth contract year of the renewal period as if such contract had been renewed on the same terms) 

Each Non-Renewal Payment shall be due and payable in accordance with the payment terms of the non-renewed contract as if such contract had
been renewed on the same terms, provided that the first payment of such Non-Renewal Payment also shall include all of the payments that would have been paid during the period beginning on the date of termination and ending on the date upon
which such first payment is made. 
  

	 	12.5	Improper ABCO Interference: ABCO shall not tortiously interfere with the contractual relationship between Evolent and any of its clients. 

 

	 	11.	The references to 42 Pa. C.S.A § 7341 in Sections 13.3.2(a) and (e) of the Agreement are hereby changed to 10 Del.C. § 5714, and the references in Section 13.3 of the Agreement
to the Laws of Pennsylvania and the Laws of the Commonwealth of Pennsylvania are hereby changed to the Laws of Delaware and the Laws of the State of Delaware. In addition, the Parties agree that (a) the third impartial arbitrator selected by
the two (2) arbitrators selected by the Parties referred to in Section 13.3 shall have at least ten (10) years of experience in hospital or health system strategy or as an executive officer of a multi-facility health system and
cannot be (or have been within the preceding ten (10) years) an Affiliate, employee or independent contractor of ABCO or Evolent and (b) for the avoidance of doubt, a Party shall be entitled to institute an action or litigation in a court,
or to commence another similar proceeding, to enforce the decision of the arbitrators pursuant to Section 13.3. 

  

	 	12.	A new Section 13.6 shall be added to the Agreement as follows: 

 13.6 General
Counsel Meetings: On a quarterly basis, the General Counsels of each Party shall meet to confer in good faith to discuss general compliance issues relating to the Agreement and, upon request at any time, share such information and documents as
are reasonably necessary to determine a Party’s compliance with its obligations under this Agreement. 
  

	 	13.	Section 14.4 of the Agreement shall be deleted in its entirety and replaced with the following: 

Governing Law and Jurisdiction: This Agreement shall be governed by and construed and enforced in accordance with the
Laws of the State of Delaware, without regard to that state or any other state’s conflict of law rules. Each Party irrevocably consents to the personal jurisdiction of the state and federal courts located in Wilmington, Delaware for any suit or
action arising from or related to this Agreement. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

- 13 - 

	B.	Defined Terms. Capitalized terms used in this Amendment and not otherwise defined shall have the meanings ascribed to them in the Agreement. 

 

	C.	Effectiveness of this Amendment; Conflicts. Except as expressly amended by this Amendment, the terms and conditions of the Agreement shall remain in full force and effect. In the event of any conflict between
this Amendment and the Agreement, this Amendment shall prevail. 

  

	D.	Warranty of Authority. Each person executing this Amendment represents that he has full power and authority to do so, and that no other authorizations or approvals of any kind are necessary. 

 

	E.	Counterparts. This Amendment may be executed in counterparts, each of which when taken together shall constitute an original. Any counterpart signature page delivered by facsimile transmission and/or electronic
mail shall be deemed to be and have the same force and effect as an originally executed signature page. 

 IN
WITNESS WHEREOF, this Amendment has been duly executed by and on behalf of the Parties as of the Amendment Effective Date. 
  

											
	EVOLENT HEALTH LLC				THE ADVISORY BOARD COMPANY
						
	Signed:		 /s/ Seth Blackley
				Signed:		 /s/ Evan Farber
		
						
	Name:		 Seth Blackley
				Name:		 Evan Farber
		
						
	Title:		 President
				Title:		 General Counsel
		

  
 - 14 - 

 EXHIBIT A 

Evolent National Support Model Departments 
  

	 	•	 	Clinical and Pharmacy Analytics 

  

	 	•	 	Clinical Operations 

  

	 	•	 	PSO 

  

	 	•	 	Pharmacy 

  

	 	•	 	IT 

  

	 	•	 	Actuarial Services 

  

	 	•	 	Strategic Client Finance 

  

	 	•	 	Compliance 

  

	 	•	 	Transformation 

  
 - 1 - 

 EXHIBIT B 

EVOLENT DATA SHARING 
 As of the
Amendment Effective Date, Evolent provides data through reports, conversations or other means that are intended to assist the recipient of the information in understanding network leakage information for purposes of optimizing value-based care
performance. The data is only for provider risk contracts / panels and is only driven by payer claims data. The analysis does not include full panel leakage analysis, does not include non-claims data or data outside the risk population and is not
provided to physicians or other constituents on an unbundled basis. Following is an example of the data provided to physicians or administrators. The data may be provided at a system level, at pod level or at an individual physician level. 

Sample Report 
 Medicare Population 

Summary of Experience Data: All Medical Claims and Encounters 
  

																																																													
	 	 	Total Population	 	 	In-Network	 	 	Out-of-Network	 
	 	 	Total Member Months:xxxxxx	 	 	Total Member Months:xxxxxx	 	 	Total Member Months:xxxxxx	 
	 Benefit
	 	Utilization
/1,000	 	 	Average
Allowed
Per
Service	 	 	Paid
PMPM	 	 	Allowed
PMPM	 	 	Patient
Pay
PMPM	 	 	Utilization
/1,000	 	 	Average
Allowed
Per
Service	 	 	Paid
PMPM	 	 	Allowed
PMPM	 	 	Patient
Pay
PMPM	 	 	Utilization
/1,000	 	 	Average
Allowed
Per
Service	 	 	Paid
PMPM	 	 	Allowed
PMPM	 	 	Patient
Pay
PMPM	 
	 Facility Inpatient Subtotal
	 	 	217.3	  	 	$	11,711	  	 	$	200.86	  	 	$	212.04	  	 	$	11.18	  	 	 	208.4	  	 	$	11,644	  	 	$	191.51	  	 	$	202.20	  	 	$	10.69	  	 	 	8.9	  	 	$	13,286	  	 	$	9.34	  	 	$	9.84	  	 	$	0.50	  
	 Facility Outpatient Subtotal
	 				 				 	$	115.18	  	 	$	124.64	  	 	$	9.46	  	 				 				 	$	113.27	  	 	$	122.65	  	 	$	9.37	  	 				 				 	$	1.91	  	 	$	2.00	  	 	$	0.09	  
	 Professional Subtotal
	 				 				 	$	204.18	  	 	$	223.05	  	 	$	18.87	  	 				 				 	$	197.49	  	 	$	216.27	  	 	$	18.77	  	 				 				 	$	6.69	  	 	$	6.78	  	 	$	0.09	  
	 Other Subtotal
	 				 				 	$	20.23	  	 	$	24.16	  	 	$	3.93	  	 				 				 	$	13.69	  	 	$	14.99	  	 	$	1.30	  	 				 				 	$	6.54	  	 	$	9.16	  	 	$	2.63	  
	 Additional Benefits Subtotal
	 				 				 	$	2.42	  	 	$	2.70	  	 	$	0.28	  	 				 				 	$	2.20	  	 	$	2.48	  	 	$	0.28	  	 				 				 	$	0.22	  	 	$	0.22	  	 	$	0.00	  
	 Total Medical Cost
	 				 				 	$	542.87	  	 	$	586.58	  	 	$	43.72	  	 				 				 	$	518.17	  	 	$	558.58	  	 	$	40.41	  	 				 				 	$	24.70	  	 	$	28.00	  	 	$	3.30	  

  
 - 1 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]